Article
Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Cancer letters - 1 Nov 2016
Zhang Zhengle, Duan Qingke, Zhao Hengqiang, Liu Tao, Wu Heshui, Shen Qiang, Wang Chunyou, Yin Tao
Abstract excerpt
Gemcitabine, the standard chemotherapy drug for advanced pancreatic cancer, has shown limited benefits because of profound chemoresistance. However, the mechanism involved remains unclear. Cancer stem cells exhibit great tumorigenicity and are closely correlated with drug resistance and tumor relapse. In this study, we demonstrated that certain doses of gemcitabine increased the ratios of CD24+ and CD133+ cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
